# idiopathic pulmonary fibrosis (IPF) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 73990
- Completion tokens: 54134
- Reasoning tokens: 18744
- Total tokens: 128124
- API requests reported: 6
- Elapsed seconds: 168.392
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: MiniMax

---
<think>Let me carefully analyze this task. The user is asking for a multidimensional interpretation of prognostic transcriptomic data for idiopathic pulmonary fibrosis (IPF) with all-cause mortality as the endpoint.

**Data Quality Warning:**
Looking at the input data, I need to identify several critical issues:
1. The first 10 rows have essentially impossible HR values: HR = 1.9287498e-22 (protective) or HR = 5.1847055e+21 (risk). These are degenerate/numerical artifacts - HR values of 1e-22 or 1e+21 are biologically impossible. P = 0 is also impossible in a strict statistical sense.
2. The P values and FDR values of exactly 0 are suspicious - they suggest numerical underflow rather than genuine statistical significance.
3. Several entries are control probes (CONTROL_A_33_P3222196, CONTROL_A_33_P3345409) or non-standard identifiers (DKFZP434L187, XLOC_003303, FAM75A2).
4. The genes like MIR221, IHH, HCN4, OR2M2, FAM75A2, DYDC2 are odd - MIR221 is a microRNA, HCN4 is a cardiac ion channel, OR2M2 is an olfactory receptor - these don't typically associate with lung fibrosis biology.
5. Several lincRNAs and ESTs (lincRNA:chr2:74193717-74210392_R, BX117289, AK309441, etc.) are included.
6. 29 duplicated genes/probes are noted.

These indicate significant data quality issues. The user has asked for a comprehensive biological interpretation, but I need to:
1. First, clearly state the data quality issues.
2. Then, despite these issues, attempt to provide an interpretation of the remaining biologically meaningful genes.

**Substantive genes with plausible HR values (HR > 1, FDR < 1e-4):**
- LOC100128226 (HR=0.007) - protective, but only 1 gene in the "protective" category with valid HR
- CYP4F3 (HR=3.78) - cytochrome P450
- HTRA1 (HR=4.30) - serine protease, ECM remodeling
- FHL2 (HR=2.76) - four-and-a-half LIM domains protein 2
- SLCO4A1 (HR=2.97) - solute carrier organic anion transporter
- LOC284751 - unknown
- GALNT14 (HR=3.11) - polypeptide N-acetylgalactosaminyltransferase
- BMP6 (HR=3.05) - bone morphogenetic protein 6
- MRVI1-AS1 (HR=3.23) - lncRNA
- S100A12 (HR=2.53) - calgranulin, neutrophil marker
- RAB3IL1 (HR=3.84) - RAB3A interacting protein
- NRG1 (HR=2.76) - neuregulin 1, growth factor
- S100A14 (HR=2.57) - S100 calcium binding protein
- CEACAM6 (HR=2.66) - epithelial marker
- SLC6A8 (HR=3.21) - creatine transporter
- PROK2 (HR=3.65) - prokineticin 2
- GPR110 (HR=2.27) - G protein-coupled receptor
- KCNJ15 (HR=3.58) - potassium channel
- MRVI1 (HR=3.85)
- CEACAM7 (HR=2.31)
- MERTK (HR=3.70) - TAM receptor tyrosine kinase
- METTL7B (HR=3.34) - methyltransferase
- PKP3 (HR=2.50) - plakophilin
- LRRC70 (HR=3.49)
- MUC1 (HR=2.32) - mucin
- HGF (HR=2.93) - hepatocyte growth factor
- DYSF (HR=3.47) - dysferlin
- PRSS8 (HR=2.57) - prostasin
- SLC7A11 (HR=3.52) - cystine transporter (xCT)
- SLC34A2 (HR=2.27) - sodium-phosphate cotransporter (alveolar type II cell marker)
- TPST1 (HR=2.92) - tyrosylprotein sulfotransferase
- AGR3 (HR=2.40)
- FAM198B (HR=3.44)
- KANK1 (HR=3.59) - KN motif and ankyrin repeat domains
- MMP25 (HR=3.26) - matrix metalloproteinase
- TM4SF1 (HR=2.57)
- MET (HR=2.53) - MET proto-oncogene
- CXCR1 (HR=3.28) - chemokine receptor
- SPRY2 (HR=3.26) - Sprouty RTK signaling antagonist
- MGAM (HR=2.61)
- MTSS1 (HR=2.45)
- MAL2 (HR=2.44)
- F5 (HR=2.55) - coagulation factor V
- ACOX2 (HR=3.18) - acyl-CoA oxidase
- ALDH1A3 (HR=2.27) - aldehyde dehydrogenase
- ANKRD22 (HR=2.56)
- STEAP4 (HR=3.03) - metalloreductase
- CXCL14 (HR=2.38) - chemokine
- BASP1 (HR=3.77)
- CHST15 (HR=2.99) - sulfotransferase
- RAB3D (HR=3.08)
- MARCKS (HR=4.00)
- FBLIM1 (HR=2.59)
- KRT23 (HR=2.59)
- FAM20A (HR=3.27)
- CCL7 (HR=3.02) - chemokine
- RGL1 (HR=3.27)
- EMP2 (HR=2.26)
- SLC39A8 (HR=3.22) - ZIP8 zinc transporter
- SOD3 (HR=2.37) - extracellular superoxide dismutase
- EFEMP1 (HR=2.33) - EGF-containing fibulin-like ECM protein
- SPRR1A (HR=2.28)
- MUC21 (HR=2.10)
- SFTA2 (HR=2.25)
- PTP4A3 (HR=2.58)
- STAB1 (HR=3.29)
- SUSD2 (HR=2.31)
- IRX2 (HR=2.22)
- SELL (HR=2.37) - selectin
- KRT17 (HR=2.19)
- SFTPB (HR=2.66) - surfactant protein B
- ENAH (HR=2.03)
- HS3ST1 (HR=3.24)
- MCTP2 (HR=2.34)
- CXCL1 (HR=2.99) - chemokine
- CD177 (HR=2.72) - neutrophil marker
- VGF (HR=2.72)
- PRSS23 (HR=2.25)
- SSTR2 (HR=2.73) - somatostatin receptor
- SPP1 (HR=3.40) - osteopontin

**Biological programs to consider:**

1. **Epithelial injury and aberrant epithelial remodeling** - MUC1, MUC21, SFTPB, SLC34A2 (ATII marker), AGR3, SUSD2, KRT17, KRT23, SPRR1A, MAL2, PKP3, ALDH1A3, EMP2, EFEMP1, CEACAM6, CEACAM7, TPST1, CHST15, GALNT14, FAM20A - these are all hallmarks of damaged/regenerating epithelium.

2. **ECM remodeling and fibrosis** - HTRA1, MMP25, FBLIM1, EFEMP1, MARCKS, SPP1, SOD3, BMP6, STAB1, STEAP4 - regulators of extracellular matrix.

3. **Neutrophilic inflammation / innate immune activation** - CXCL1, CXCL14, CCL7, CXCR1, S100A12, S100A14, CD177, SELL, SPP1 - neutrophil chemotaxis and antimicrobial response (matches the GO: Neutrophil Migration annotation).

4. **Growth factor signaling and receptor tyrosine kinase programs** - HGF, MET, NRG1, MERTK, SPRY2, PTP4A3, RGL1, VGF - hepatocyte and other growth factor pathways.

5. **Ion transport / membrane biology** - KCNJ15, SLC6A8, SLC7A11, SLC34A2, SLC39A8, SLCO4A1, KCNJ15 - solute carriers and channels.

6. **Metabolic reprogramming / redox** - SOD3, ACOX2, ALDH1A3, STEAP4, CYP4F3, SLC7A11 (cystine/GSH).

**Network evidence:**
- EGFR: EFEMP1, HGF, MET, MUC1, NRG1 (5 selected genes) - growth factor receptor module
- CD44: SELL, SLC7A11, SPP1 - adhesion/inflammation module
- CXCL5: CXCL1, CXCL14, CXCR1 - chemokine module
- CXCL6: CCL7, CXCL1, CXCR1 - chemokine module
- FN1: CEACAM6, HGF, SPP1 - ECM/integrin module

**Evidence grounding:**
- Independent cohort validation: NOT AVAILABLE
- Pathway enrichment from RAG: GO Neutrophil Migration, Negative Regulation of Lamellipodium Organization, Antimicrobial Humoral Immune Response Mediated by Antimicrobial Peptide; KEGG: Viral protein interaction with cytokine and cytokine receptor, Epithelial cell signaling in H. pylori, Chemokine signaling

**Literature:**
- HTRA1, SPP1, MUC1 are well-known IPF genes.
- SPP1 (osteopontin) is a validated IPF prognostic marker.
- SFTPB is a surfactant gene linked to IPF.
- KRT23, FAM198B, S100A14 have varied literature not directly IPF-focused.
- SFTA2 has been linked to lung cancer risk, possibly related to surfactant function.

**Plan for the response:**

1. **Data quality warning** - clearly flag the suspicious HR/P/FDR=0 entries
2. **Overall biological interpretation** - integrate epithelial remodeling, ECM, neutrophilic inflammation
3. **Core biological programs** - 5 programs max
4. **Key genes/modules** - 10 max
5. **Validation priorities** - 5 max
6. **Evidence grounding** - distinguish direct vs external evidence
7. **Limitations** - data quality, confounding, etc.

Let me draft the response carefully, ensuring I:
- Treat HR=1e-22 and 1e+21 as artifacts (not interpretable biology)
- Focus on genes with plausible HR (LOC100128226, CYP4F3, HTRA1, etc.)
- Note that only 1 protective gene has valid HR
- Note 7 protective vs 93 risk-associated genes (per ledger direction counts)
- Don't elevate weak signals
- State that independent validation was not performed
- Distinguish data-quality issues clearly

Let me write the response now.

Format: Markdown, web chat. End with a complete sentence.</think>

## Data-quality warning (read first)

Before any biological interpretation, the supplied survival ledger has multiple features that warrant explicit caution:

- **Degenerate HRs.** The first ten rows include `HR = 1.929e-22` (e.g., MIR221, IHH, FAM75A2, OR2M2, DYDC2) and `HR = 5.185e+21` (e.g., CONTROL_A_33_P3222196, HCN4, CONTROL_A_33_P3345409, DKFZP434L187). These values are not biologically plausible hazard ratios; they almost certainly reflect numerical artefacts (overflow/underflow or a mis-signed coefficient) rather than genuine survival effects. The single protective gene with a plausible effect size is `LOC100128226` (HR = 0.00703, FDR = 4.8e-35).
- **P = 0 / FDR = 0** are reported for the same rows; in continuous survival models these typically indicate numerical underflow rather than infinite evidence.
- **Probe / non-gene entries** are present (CONTROL_A_33_P probes, `lincRNA:` identifiers, ESTs like BX117289, AK096792, AK309441, and locus IDs LOC100128226, LOC284751, LOC388210, LOC93444, LOC100506328), whose biology cannot be unambiguously assigned.
- **29 duplicate probes** across multiple genes (e.g., FHL2, S100A12, KCNJ15, MERTK, NRG1, SLC6A8, KANK1, MMP25, TM4SF1, CXCL1, etc.) inflate apparent cross-source corroboration but represent the same transcript measured by multiple probes.
- **Independent-cohort replication is not available** in the supplied evidence pack; external pathway, interaction, tissue, drug, and literature records are contextual annotations only.

The interpretation below therefore relies on the **93 genes with HR in the biologically plausible range (HR ≈ 2–4)** and treats the artefacts above as non-informative, while flagging throughout that the underlying statistical layer is fragile.

---

## 1. Overall biological interpretation

The 100 selected transcripts are dominated (93/100) by **risk-associated** features whose hazard ratios cluster between ~2.0 and ~4.3, with no coherent protective program beyond a single plausible entry (`LOC100128226`, an uncharacterised locus). The biology they collectively point to in IPF lung is consistent with three converging axes:

- **Damaged / remodelling airway and alveolar epithelium** — mucins (MUC1, MUC21), surfactant protein B (SFTPB), the alveolar type II phosphate transporter (SLC34A2), keratins (KRT17, KRT23), the barrier/regeneration markers SPRR1A, SUSD2, AGR3, MAL2, PKP3, and glycosylation/sulfation enzymes (GALNT14, CHST15, TPST1, FAM20A).
- **Stromal / extracellular-matrix remodelling and fibroproliferation** — HTRA1, MMP25, FBLIM1, EFEMP1, SPP1 (osteopontin), MARCKS, STAB1, STEAP4, BMP6, and FN1-adhesion-linked CEACAM6.
- **Innate / neutrophilic inflammatory activation** — neutrophil chemoattractants CXCL1, CXCL14, CCL7; the neutrophil-surface markers CD177, SELL, CEACAM6; the S100 alarmins S100A12 and S100A14; and the receptor CXCR1. The retrieved GO annotations (Neutrophil Migration, Antimicrobial Humoral Response Mediated by Antimicrobial Peptide) and KEGG (Chemokine signaling) are driven almost entirely by this cluster.

A secondary, weaker axis is **growth-factor / RTK signalling** (HGF, MET, NRG1, MERTK, SPRY2, PTP4A3, RGL1, VGF) that intersects the epithelial and stromal programs via the EGFR / MET / FN1 network neighbourhood. A separate, smaller **ion-transport / solute-carrier axis** (SLC6A8, SLC7A11, SLC34A2, SLC39A8, SLCO4A1, KCNJ15) likely reflects both epithelial injury and altered cellular metabolism, while **redox / metabolic reprogramming** genes (SOD3, ACOX2, ALDH1A3, STEAP4, CYP4F3, SLC7A11/xCT) suggest glutathione/oxidative stress handling.

Taken together, the prognostic signature is not a single programme but a **layered signal: epithelial stress + ECM reorganisation + neutrophil-dominant innate immunity**, with growth-factor and metabolic layers riding on top. In IPF, this combination is mechanistically consistent with an aggressive fibroproliferative, neutrophil-rich end-stage lung, but the present data do not show that the signature is causal — only that it is associated with shorter survival.

---

## 2. Core biological programs (≤ 5)

### Program 1 — Altered / injured airway-alveolar epithelium
- **Direction:** risk-associated (HR 2.0–3.0).
- **Major supporting genes:** MUC1 (HR 2.32), MUC21 (HR 2.10), SFTPB (HR 2.66), SLC34A2 (HR 2.27), AGR3 (HR 2.40), SUSD2 (HR 2.31), KRT17 (HR 2.19), KRT23 (HR 2.59), SPRR1A (HR 2.28), MAL2 (HR 2.44), PKP3 (HR 2.50), ALDH1A3 (HR 2.27), EMP2 (HR 2.26), EFEMP1 (HR 2.33), CEACAM6 (HR 2.66), CEACAM7 (HR 2.31), TPST1 (HR 2.92), GALNT14 (HR 3.11), CHST15 (HR 2.99), FAM20A (HR 3.27), HS3ST1 (HR 3.24).
- **Standardised terms:** GO:0007585 respiratory gaseous exchange / GO:0042060 wound healing; Reactome "Surfactant metabolism" (R-HSA-5683828), KEGG "Mucin type O-glycan biosynthesis".
- **Why these genes together:** they are canonical markers of bronchial and alveolar epithelial identity, mucociliary barrier function, surfactant production, and post-injury regeneration. Their joint risk association is consistent with a transcriptomic state in which injured / metaplastic / hyperplastic epithelium is a marker of worse prognosis.
- **Strength and limits:** Strong intra-program coherence; consistent with established IPF biology (MUC1, MUC21, SFTPB and SLC34A2 are repeatedly reported as altered in IPF). However, **independent cohort replication was not performed**, and a keratin/mucin signature can also reflect sampling of airway-rich regions (a composition confounder — see §6).

### Program 2 — ECM remodelling and fibroproliferation
- **Direction:** risk-associated (HR 2.3–4.3).
- **Major supporting genes:** HTRA1 (HR 4.30, top non-degenerate HR), MMP25 (HR 3.26), FBLIM1 (HR 2.59), EFEMP1 (HR 2.33), MARCKS (HR 4.00), SPP1 (HR 3.40, osteopontin), STAB1 (HR 3.29), STEAP4 (HR 3.03), BMP6 (HR 3.05), CEACAM6 (HR 2.66, FN1-adhesion network), RGL1 (HR 3.27), KANK1 (HR 3.59), BASP1 (HR 3.77).
- **Standardised terms:** Reactome "Extracellular matrix organization" (R-HSA-1474244); KEGG "TGF-beta signaling pathway"; Hallmark "Epithelial-mesenchymal transition".
- **Why these genes together:** they encode or regulate collagen/fibulin processing (HTRA1, EFEMP1, FBLIM1), matrix metalloproteinase activity (MMP25), integrin/focal-adhesion signalling (BASP1, MARCKS, KANK1, CEACAM6 via FN1), and profibrotic cytokines (BMP6, SPP1). The presence of SPP1 (osteopontin) and HTRA1 — both previously linked to IPF severity in independent cohorts — supports the biological plausibility of this program.
- **Strength and limits:** Internally coherent and supported by a credible literature record (HTRA1, SPP1, EFEMP1, SPP1 in IPF). The retrieved network module **FN1 ↔ CEACAM6, HGF, SPP1** is pathway co-membership plus curated interaction evidence and is **not** direct physical binding evidence per se. Limits: the SPP1 prognostic signal in IPF is well established in external cohorts (independent validation), but that external replication is **not in the supplied dataset**, so this remains a supported rather than validated program here.

### Program 3 — Neutrophilic / innate immune activation
- **Direction:** risk-associated (HR 2.3–3.5).
- **Major supporting genes:** CXCL1 (HR 2.99), CXCL14 (HR 2.38), CCL7 (HR 3.02), CXCR1 (HR 3.28), S100A12 (HR 2.53), S100A14 (HR 2.57), CD177 (HR 2.72), SELL (HR 2.37), SPP1 (HR 3.40, also ECM), and the FN1/CD44 network neighbours.
- **Standardised terms:** GO:1990266 Neutrophil Migration; GO:0061844 Antimicrobial Humoral Immune Response Mediated by Antimicrobial Peptide; KEGG "Chemokine signaling pathway"; Reactome "Neutrophil degranulation" (R-HSA-6798695).
- **Why these genes together:** CD177 and SELL are neutrophil-surface proteins; S100A12/A14 are neutrophil-derived alarmins; CXCL1, CXCL14 and CCL7 are neutrophil-active chemokines; CXCR1 is the canonical neutrophil chemokine receptor. The retrieved GO terms are driven by exactly this set.
- **Strength and limits:** This is the single best-supported program in the cohort at the **annotation level** (GO/KEGG terms converge here). Limits: in IPF, neutrophilia in BAL and blood is reproducibly associated with progression and mortality, but the input is bulk lung tissue; therefore this program may partly reflect **infiltrating neutrophil abundance rather than a parenchymal transcriptional program** — a critical caveat (see §6). Independent statistical replication in a second IPF cohort is not present in the supplied pack.

### Program 4 — Growth-factor / RTK signalling
- **Direction:** risk-associated (HR 2.5–3.7).
- **Major supporting genes:** HGF (HR 2.93), MET (HR 2.53), NRG1 (HR 2.76), MERTK (HR 3.70), SPRY2 (HR 3.26), PTP4A3 (HR 2.58), RGL1 (HR 3.27), VGF (HR 2.72), with EFEMP1 and MUC1 also appearing in the retrieved **EGFR network neighbourhood** (EFEMP1, HGF, MET, MUC1, NRG1).
- **Standardised terms:** Reactome "Signaling by Receptor Tyrosine Kinases" (R-HSA-9006934); KEGG "EGFR tyrosine kinase inhibitor resistance".
- **Why these genes together:** they cluster around HGF/MET and neuregulin/EGFR-family ligand signalling, with MERTK (a TAM-family RTK expressed on macrophages and epithelial cells) and SPRY2 (a feedback inhibitor of FGF/RTK signalling, whose elevated level likely reflects compensation). RGL1 and PTP4A3 are Ras/Rho-pathway effectors.
- **Strength and limits:** Network-coherent (STRING neighbourhood with EGFR), but the STRING evidence is mixed physical/curated/co-expression and is **not** direct biophysical interaction evidence. Limits: the HGF/MET axis is a known IPF pathway, but the prognostic value of these specific transcripts in IPF mortality is not independently replicated in the supplied dataset.

### Program 5 — Solute transport, redox and metabolic stress
- **Direction:** risk-associated (HR 2.2–3.5).
- **Major supporting genes:** SLC6A8 (creatine, HR 3.21), SLC7A11 (cystine/xCT, HR 3.52), SLC34A2 (phosphate, HR 2.27, also Program 1), SLC39A8/ZIP8 (zinc, HR 3.22), SLCO4A1 (organic anion, HR 2.97), KCNJ15 (K⁺ channel, HR 3.58), SOD3 (extracellular superoxide dismutase, HR 2.37), ACOX2 (FAO, HR 3.18), ALDH1A3 (retinoic-acid synthesis, HR 2.27), STEAP4 (metal/copper reductase, HR 3.03), CYP4F3 (leukotriene/cytochrome P450, HR 3.78), HTRA1 (also Program 2).
- **Standardised terms:** GO:0005215 transporter activity; Reactome "SLC-mediated transmembrane transport" (R-HSA-425407); Hallmark "Reactive oxygen species pathway".
- **Why these genes together:** altered epithelial ion/solute transport (SLC34A2, KCNJ15), cystine import / glutathione synthesis (SLC7A11), fatty-acid β-oxidation (ACOX2), alde detoxification (ALDH1A3), and extracellular antioxidant defence (SOD3) form a coherent redox/transport cluster. SLC7A11/xCT is of particular interest as it is both a ferroptosis and a GSH-pathway regulator.
- **Strength and limits:** Cohesive in annotation terms; the relevance to IPF prognosis is biologically plausible but **not independently replicated** in this evidence pack. Several members (SLC34A2, CYP4F3) appear in retrieved GWAS/literature for lung phenotypes, but the direction of effect on mortality in independent IPF cohorts is not established here.

---

## 3. Key genes / interaction modules (≤ 10)

For each, I state the **type of relationship** explicitly. STRING "edges" here are aggregated network proximity — a mix of curated/physical/co-expression evidence — and are **not equivalent to direct physical interaction**.

1. **HTRA1** — risk-associated, HR ≈ 4.30 (top non-degenerate HR). Programs 2 (ECM) and 5 (proteostasis/stress). STRING network proximity places it near SPP1/CEACAM6 via fibulin and TGF-β co-membership; this is **pathway co-membership + co-expression**, not proven direct interaction. *Direct dataset evidence; strong external literature in IPF; supported hypothesis for prognostic biomarker / mechanistic target.*
2. **SPP1 (osteopontin)** — risk-associated, HR ≈ 3.40. Programs 2 (ECM) and 3 (innate immunity). Recurs in STRING module **FN1 ↔ CEACAM6, HGF, SPP1** and **CD44 ↔ SELL, SLC7A11, SPP1**. These are mixed curated/co-expression edges; the SPP1–CD44 ligand–receptor relation is a curated direct interaction in external databases (and is the most defensible direct physical link in the set). *Direct dataset evidence; well-established IPF prognostic biomarker in independent external cohorts (not replicated here).*
3. **MUC1** — risk-associated, HR ≈ 2.32. Program 1 (epithelium). STRING neighbourhood with EGFR (with HGF, MET, NRG1, EFEMP1). Relationship: pathway co-membership / co-expression in EGFR signalling, not direct binding. *Direct dataset evidence; supported hypothesis.*
4. **HGF / MET pair** — HGF HR ≈ 2.93, MET HR ≈ 2.53. Program 4. HGF–MET is a **direct ligand–receptor interaction** supported by external curated databases; the prognostic co-upregulation in IPF is biologically plausible. *Direct dataset evidence + curated external interaction; supported hypothesis.*
5. **CXCL1 / CXCL14 / CCL7 / CXCR1 neutrophil-chemokine module** — risk-associated (HR 2.4–3.3). Program 3. STRING neighbourhood **CXCL5/CXCL6** anchors these; relationships are ligand–receptor pairs (CXCL1/CCL7–CXCR1) — these are **direct receptor–ligand interactions** in curated Reactome/KEGG. CXCL14's receptor is still uncertain (CXCR4/ACKR3 have been proposed but are not canonical). *Direct dataset evidence + curated chemokine signalling; supported hypothesis — see §6 for the confound caveat.*
6. **S100A12 / S100A14 / CD177 / SELL neutrophil module** — risk-associated (HR 2.4–2.7). Program 3. CD177 and SELL are neutrophil-surface markers; S100A12/A14 are neutrophil alarmin secretions. Relationships here are **co-expression / co-membership in neutrophil-degranulation Reactome**, not necessarily direct binding between these specific proteins. *Direct dataset evidence + pathway co-membership; supported hypothesis, but likely partly a cell-composition proxy.*
7. **SLC7A11 (xCT)** — risk-associated, HR ≈ 3.52. Programs 3 (CD44-adjacent) and 5. STRING module **CD44 ↔ SELL, SLC7A11, SPP1** indicates co-expression / curated neighbourhood; SLC7A11 is the cystine/glutamate antiporter central to GSH synthesis and ferroptosis. *Direct dataset evidence; mechanistic hypothesis worth testing in IPF-relevant models.*
8. **EFEMP1 (fibulin-3)** — risk-associated, HR ≈ 2.33. Programs 1 and 2; STRING EGFR neighbourhood. EFEMP1 binds ECM and is implicated in fibrotic remodelling; relationship to EGFR module is co-expression rather than direct binding. *Direct dataset evidence; supported hypothesis.*
9. **NRG1** — risk-associated, HR ≈ 2.76. Program 4 (EGFR-family ligand). NRG1–HER3/HER4 is a **direct ligand–receptor interaction** in curated databases; its role in IPF specifically is not well established. *Direct dataset evidence + curated interaction; exploratory hypothesis for IPF.*
10. **SLC34A2 + SFTPB alveolar-type-II module** — risk-associated (HR 2.27 and 2.66). Program 1. These are direct ATII-cell markers; their co-risk association is most parsimoniously explained as a **cell-composition proxy** (loss or expansion of ATII cells; see §6). Relationship: pathway co-membership / co-expression in surfactant biology.

---

## 4. Validation priorities (≤ 5)

1. **HTRA1 and SPP1 as a composite prognostic biomarker (Biomarker).**
   - *Why prioritise:* HTRA1 has the largest non-degenerate HR (~4.3) in the cohort, and SPP1 has the strongest external IPF-prognosis literature. Both sit in Programs 2 and 3.
   - *Evidence in dataset:* HR ≈ 4.30 (HTRA1, FDR 2.6e-6) and HR ≈ 3.40 (SPP1, FDR 4.0e-5); both appear in curated FN1 and CD44 STRING neighbourhoods.
   - *External evidence:* SPP1 is a repeatedly validated IPF prognostic biomarker (independent external cohorts); HTRA1 has known ECM protease activity and IPF associations in literature.
   - *Next step:* qPCR / digital spatial profiling of HTRA1 and SPP1 in an independent IPF cohort with mortality follow-up; combine with clinical covariates (GAP stage) to test added prognostic value.
   - *Status:* **Supported hypothesis** for SPP1 (externally established but not replicated in the present dataset) and **exploratory hypothesis** for HTRA1 as a quantitative prognostic biomarker.

2. **Neutrophil-program signature as a confounding / composition check (Confounding or composition check).**
   - *Why prioritise:* the neutrophil module (CXCL1, CXCL14, CCL7, CXCR1, S100A12, S100A14, CD177, SELL) drives most of the GO enrichment. It is biologically plausible that the prognostic signal is at least partly an **infiltrating-neutrophil signature** rather than a parenchymal transcriptional program.
   - *Evidence in dataset:* 7+ neutrophil-related genes are risk-associated with HR 2.3–3.3 and FDR < 4e-5.
   - *External evidence:* BAL and blood neutrophil counts are associated with IPF progression in external cohorts, but neutrophil transcripts in **bulk lung tissue** may reflect admixed immune cells rather than epithelial/stromal biology.
   - *Next step:* deconvolve the bulk signal with cell-type signatures (e.g., CIBERSORTx, MCP-counter) and re-estimate HR after adjustment for inferred neutrophil fraction; or, ideally, validate in neutrophil-depleted single-cell RNA-seq.
   - *Status:* **Exploratory hypothesis** that the neutrophil signature is a composition artefact.

3. **HGF / MET / NRG1 growth-factor module — therapeutic target hypothesis (Therapeutic target).**
   - *Why prioritise:* all three are risk-associated, sit in a coherent STRING EGFR neighbourhood, and have approved or investigational drugs (MET inhibitors, HER3 antibodies). The existence of drugs does not establish efficacy in IPF.
   - *Evidence in dataset:* HGF HR ≈ 2.93, MET HR ≈ 2.53, NRG1 HR ≈ 2.76; EGFR neighbourhood shared with MUC1 and EFEMP1.
   - *External evidence:* HGF/MET axis has mechanistic links to fibroproliferation; NRG1/HER3 biology is well established in oncology but under-explored in IPF.
   - *Next step:* measure HGF, MET and NRG1/HER3 in IPF tissue and test whether small-molecule or antibody inhibition attenuates fibroblast activation in IPF-derived lung organoids or precision-cut lung slices.
   - *Status:* **Exploratory hypothesis** for IPF; the existence of drugs is not evidence of therapeutic efficacy.

4. **SLC7A11 / xCT and ferroptosis in IPF fibroproliferation (Mechanistic hypothesis).**
   - *Why prioritise:* SLC7A11 has HR ≈ 3.52 and sits at the crossroads of oxidative stress, GSH biology and ferroptosis — a pathway of growing interest in chronic lung disease.
   - *Evidence in dataset:* SLC7A11 risk-association; STRING CD44 module co-membership with SPP1 and SELL.
   - *External evidence:* ferroptosis/GSH biology is implicated in epithelial injury in IPF in published work; pharmacologic modulation of xCT is feasible (e.g., erastin, sulfasalazine).
   - *Next step:* quantify lipid peroxidation and GSH in IPF vs control lung tissue; test whether SLC7A11 expression correlates with ferroptosis markers in IPF fibroblasts and ATII cells.
   - *Status:* **Exploratory hypothesis.**

5. **HTRA1 – SPP1 – EFEMP1 ECM axis as a network-level interaction hypothesis (Interaction / network hypothesis).**
   - *Why prioritise:* HTRA1, SPP1, EFEMP1 and CEACAM6 are interconnected in STRING (FN1 module) and converge on ECM remodelling, but the specific physical/compositional relationships need direct test.
   - *Evidence in dataset:* shared risk-association; co-membership in FN1 and CD44 STRING neighbourhoods; EFEMP1 and CEACAM6 also adjacent to EGFR.
   - *External evidence:* HTRA1 cleaves fibulins and LTBP-1 (curated; some direct substrate evidence); SPP1 binds CD44 and integrins (direct interaction in external curated databases). EFEMP1/HTRA1 substrate relationship is **putative and partly literature-supported, not proven as a direct HTRA1–EFEMP1 cleavage pair in IPF tissue**.
   - *Next step:* co-IP / proximity ligation in IPF fibroblasts; protease-substrate assays for HTRA1 on EFEMP1 and fibulin-1; test whether blocking HTRA1 alters fibulin/ECM organisation.
   - *Status:* **Supported hypothesis** for the network direction; **exploratory** for the specific cleavage relationships.

---

## 5. Evidence grounding (per program / gene / priority)

| Claim | Direct dataset | External annotation | Independent stat. replication | Independent support quality |
|---|---|---|---|---|
| Epithelial injury program (Program 1) | Yes — 20+ genes, HR ≈ 2.0–3.3, FDR < 4e-5 | GO/Reactome surfactant, mucin-type O-glycan | Not present in this pack | Plausible but not replicated |
| ECM remodelling program (Program 2) | Yes — HTRA1, SPP1, MMP25, EFEMP1, MARCKS, FBLIM1, BMP6 etc. | Reactome ECM organisation; FN1 STRING module | SPP1 has external IPF literature; HTRA1 in IPF literature | One member externally supported, others not |
| Neutrophil program (Program 3) | Yes — CXCL1, CXCL14, CCL7, CXCR1, S100A12, S100A14, CD177, SELL | GO:1990266, GO:0061844, KEGG chemokine, Reactome neutrophil degranulation | Not in this pack | Plausible; partly confounded by composition |
| RTK / growth-factor program (Program 4) | Yes — HGF, MET, NRG1, MERTK, SPRY2 | Reactome signalling by RTKs; STRING EGFR neighbourhood | Not in this pack | Plausible; HGF/MET better supported externally |
| Solute / redox program (Program 5) | Yes — SLC6A8, SLC7A11, SLC34A2, SLC39A8, SLCO4A1, KCNJ15, SOD3, ACOX2, ALDH1A3 | Reactome SLC transport; Hallmark ROS | Not in this pack | Plausible; SLC34A2 has GWAS links to lung phenotypes |
| HGF–MET / NRG1–HER3 interactions | Indirect — co-risk association | Curated direct ligand–receptor interactions in external databases | Not in this pack | Externally supported (independent curated databases), not replicated here |
| SPP1–CD44 interaction | Indirect — co-risk association | Direct ligand–receptor (curated) | External IPF literature supports prognostic role | Best-supported direct interaction claim |

**Conflicts and gaps.** No conflicting evidence between sources was retrieved, but there is a clear gap: **independent-cohort survival statistics are absent**, so "supported" here means supported by retrieved annotation and literature context, not by replication. Within the neutrophil cluster, the GO/KEGG annotations are strongly supportive, but the most parsimonious alternative explanation is cell-composition confounding (§6) — these are not mutually exclusive but are not distinguishable from the supplied data.

---

## 6. Limitations and alternative explanations

1. **Degenerate / artefactual HRs in 10/100 rows** (MIR221, IHH, HCN4, OR2M2, FAM75A2, DYDC2, XLOC_003303, CONTROL_A_33_P3222196, CONTROL_A_33_P3345409, DKFZP434L187). These cannot be interpreted biologically and may indicate a model fit or input-format issue in the upstream survival step. *Investigation:* re-fit Cox models with stable convergence and report HRs that are not at numerical limits; check whether these correspond to near-monotone covariates or to probes with no variation in one arm.
2. **Tissue / cell-composition confounding (esp. neutrophil module).** IPF lung contains variable proportions of neutrophils, macrophages, fibroblasts, and epithelium. Risk-associated neutrophil transcripts (CXCL1, CXCL14, CD177, SELL, S100A12/A14) likely partly reflect admixed immune cells. *Investigation:* cell-type deconvolution, paired single-cell / spatial transcriptomics, and re-estimation of HR after adjusting for inferred neutrophil fraction.
3. **Probes, lncRNAs and ESTs with uncertain gene identity** (`lincRNA:chr*:...`, BX117289, AK096792, AK309441, XLOC_003303, FAM75A2, DKFZP434L187, FAM40B). These contribute to FDR inflation without yielding interpretable biology. *Investigation:* re-annotate against a current reference (Ensembl / RefSeq) and restrict the prognostic table to well-mapped protein-coding genes.
4. **Single-cohort survival model, no external replication, no covariate adjustment visible in the supplied table.** The supplied HRs are unadjusted; sex, age, smoking, GAP stage, treatment with antifibrotics (pirfenidone / nintedanib) and disease severity are not accounted for. Several genes (HTRA1, MMP25, S100A12, MERTK) are known to vary with disease severity and smoking. *Investigation:* multivariable Cox models with clinical covariates, plus a pre-specified independent replication cohort.
5. **Association vs causation.** Even for the most robust signals (HTRA1, SPP1), the supplied analysis shows association with mortality, not causality. The neutrophil program may mark advanced disease rather than drive it; the ECM program may be downstream of TGF-β rather than its initiator. Mechanistic claims require functional experiments (CRISPR, inhibitors, organoids), which are out of scope here.

---

**Bottom line.** Within the biologically interpretable subset of the supplied data, the prognostic signal for all-cause mortality in IPF lung tissue is dominated by an **epithelial-injury + ECM-remodelling + neutrophilic-innate-immune triad**, with secondary RTK and solute/redox programmes. SPP1 and HTRA1 are the most defensible prognostic candidates, but the **independent-cohort validation that would be needed to call them validated biomarkers is not present in this evidence pack**, and a substantial fraction of the apparent neutrophil signal may reflect cell-composition confounding. The first ten rows of the supplied table should be re-fitted before the data are used downstream.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=149, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
